1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Spain Medical Devices Report Q2 2016

Spain Medical Devices Report Q2 2016

  • March 2016
  • -
  • Espicom Business Intelligence
  • -
  • 167 pages

We forecast low market growth over the forecast period, as pre-crisis import growth levels are unlikely to return. Due to its large size, the market will remain attractive to multinational and national companies. Despite cost-containment measures and SNS debts, most of the market will remain accountable to the public sector. The market will benefit from the prevalence of chronic diseases, the ageing population and digital transformation.

Table Of Contents

Spain Medical Devices Report Q2 2016

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...

Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects Summary Type 2 diabetes ...

Global Idiopathic Pulmonary Fibrosis Pipeline Analysis, 2016 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Global Idiopathic Pulmonary Fibrosis Pipeline Analysis, 2016 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

  • $ 6500
  • Industry report
  • February 2017
  • by P&S Market Research

Pipeline Overview Idiopathic pulmonary fibrosis (IPF) is referred to as progressive and chronic interstitial pneumonia without known cause. Pulmonary fibrosis is a disease in which tissue profound in lungs ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.